JP2008519049A - 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬 - Google Patents

増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬 Download PDF

Info

Publication number
JP2008519049A
JP2008519049A JP2007540099A JP2007540099A JP2008519049A JP 2008519049 A JP2008519049 A JP 2008519049A JP 2007540099 A JP2007540099 A JP 2007540099A JP 2007540099 A JP2007540099 A JP 2007540099A JP 2008519049 A JP2008519049 A JP 2008519049A
Authority
JP
Japan
Prior art keywords
formula
compound
treatment
pharmaceutically acceptable
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007540099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519049A5 (https=
Inventor
リー・フランシス・ワイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2008519049A publication Critical patent/JP2008519049A/ja
Publication of JP2008519049A5 publication Critical patent/JP2008519049A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007540099A 2004-11-04 2005-11-04 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬 Withdrawn JP2008519049A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62493704P 2004-11-04 2004-11-04
US63212204P 2004-12-01 2004-12-01
US64972205P 2005-02-03 2005-02-03
US70362805P 2005-07-29 2005-07-29
PCT/US2005/040145 WO2006052810A2 (en) 2004-11-04 2005-11-04 Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
JP2008519049A true JP2008519049A (ja) 2008-06-05
JP2008519049A5 JP2008519049A5 (https=) 2008-11-06

Family

ID=36337059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540099A Withdrawn JP2008519049A (ja) 2004-11-04 2005-11-04 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬

Country Status (13)

Country Link
US (2) US20060094728A1 (https=)
EP (1) EP1812432A4 (https=)
JP (1) JP2008519049A (https=)
KR (1) KR20070073864A (https=)
AR (1) AR053984A1 (https=)
AU (1) AU2005304863A1 (https=)
BR (1) BRPI0515721A (https=)
CA (1) CA2586649A1 (https=)
MX (1) MX2007005115A (https=)
NO (1) NO20072179L (https=)
RU (1) RU2007120710A (https=)
TW (1) TW200628156A (https=)
WO (1) WO2006052810A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518827A (ja) * 2010-02-08 2013-05-23 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
JP2013518829A (ja) * 2010-02-02 2013-05-23 南京▲か▼文迪許生物工程技術有限公司 ダサチニブの合成方法およびその中間体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
ATE505192T1 (de) * 2005-06-09 2011-04-15 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
WO2007047919A2 (en) 2005-10-20 2007-04-26 University Of South Florida Treatment of restenosis and stenosis with dasatinib
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2508523B2 (en) * 2007-10-23 2019-04-17 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
CN101891738B (zh) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
CN102643275B (zh) * 2011-02-21 2016-04-20 江苏先声药物研究有限公司 一种达莎替尼n-6晶型新的制备方法
CN102838594B (zh) * 2011-06-24 2015-06-24 南京圣和药业股份有限公司 一种达沙替尼的制备及精制方法
CA2937992A1 (en) * 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
AU2023373917A1 (en) 2022-11-02 2025-05-01 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
KR20260016906A (ko) 2023-03-17 2026-02-04 엠디엑스 메니지먼트 엘엘씨 요법의 유해효과를 개선하기 위한 조성물 및 방법
WO2025188914A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Tyrosine phosphatase inhibitor 1 (tpi-1) derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
ES2349532T3 (es) * 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
ATE481134T1 (de) * 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518829A (ja) * 2010-02-02 2013-05-23 南京▲か▼文迪許生物工程技術有限公司 ダサチニブの合成方法およびその中間体
JP2013518827A (ja) * 2010-02-08 2013-05-23 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物

Also Published As

Publication number Publication date
AU2005304863A1 (en) 2006-05-18
US20090093495A1 (en) 2009-04-09
WO2006052810A3 (en) 2007-02-08
MX2007005115A (es) 2007-06-26
CA2586649A1 (en) 2006-05-18
EP1812432A2 (en) 2007-08-01
TW200628156A (en) 2006-08-16
US20060094728A1 (en) 2006-05-04
RU2007120710A (ru) 2008-12-10
WO2006052810A2 (en) 2006-05-18
KR20070073864A (ko) 2007-07-10
BRPI0515721A (pt) 2008-08-05
AR053984A1 (es) 2007-05-30
NO20072179L (no) 2007-05-31
EP1812432A4 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
US20090093495A1 (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
JP2025131597A (ja) 固体形態
US20210403495A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
TW202027746A (zh) 用於治療三陰性乳癌之組合療法
KR101730791B1 (ko) 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
US10143692B2 (en) Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them
US20070105867A1 (en) Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
CN102086195B (zh) 达沙替尼多晶型物及其制备方法和药用组合物
CN116615426A (zh) Fgfr抑制剂和其制造和使用方法
CN108779126A (zh) 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式
WO2020244612A1 (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN104024243A (zh) 作为酪氨酸激酶抑制剂的新咪唑并吡啶衍生物
WO2011108953A1 (en) PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
CN111100117B (zh) 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用
CN110753691A (zh) 化合物
KR101663335B1 (ko) 6-（1-메틸-1ｈ-피라졸-4-일）-2-｛3-［5-（2-모르폴린-4-일-에톡시）-피리미딘-2-일］-벤질｝-2ｈ-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법
WO2021143819A1 (zh) 多环类间变性淋巴瘤激酶抑制剂的晶型
KR20230152118A (ko) 약물 조성물 및 이의 제조 방법 및 용도
TW202539679A (zh) Ｃｄｋ抑制劑的鹽型及固態型
TW202540098A (zh) Ｃｄｋ抑制劑的鹽型及固態型
WO2026050858A1 (en) Salts of ((2,3-dichlorophenyl)sulfonyl)(2,4-difluoro-3-((6-(4-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)-1h-benzo[d]imidazol-1-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)phenyl)amide, their preparation and their use as raf kinase inhibitors
TW202434607A (zh) Cdk抑制劑及其可藥用鹽的晶型以及其用途
TW202604493A (zh) Ripk2抑制劑之晶型
CN120897917A (zh) 喹唑啉ErbB抑制剂的药物形式

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080910

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100215